Junshi Bio announced its interim results for 2020, with research and development investment up 92% year-on-year!

On August 31st Junshi Bio announced its 2020 interim results.
press release, the company has made significant progress in product commercialization, clinical trials and pipeline expansion, with unaudited revenue of $575 million, up 86% year-on-year. Dr. Li Ning, CEO of
Junshi Bio, said, "Junshi Bio is an innovatively driven biopharmaceutical company with complete capabilities across the entire industry chain, from the discovery of innovative drugs, clinical research and development worldwide, mass production to commercialization.
the first half of 2020, we have overcome many challenges, supported the development and production of pipeline products, and made significant progress in clinical trials of many products.
, we also turned dangerous into an opportunity, with many years of accumulation of antibody development technology platform advantages, with domestic scientific research institutions hand in hand to fight the epidemic.
jointly developed JS016 as China's first anti-neo-coronavirus monoclonal and antibody into clinical trials, with local innovation for China and the world's disease prevention and control contribution.
Looking ahead, in the field of drug research and development, we will continue to track and explore potential targets suitable for the development of large-molecule drugs, develop new drugs in research and development, while investing appropriate resources in the field of small molecule research and development for the exploration and development of new drug targets, and carry out exploratory research in the field of cell therapy and tumor vaccines;
in production, we plan to further increase the production capacity of polymer drugs and explore new production processes to further reduce production costs.
in the commercialization, continue to improve the marketing and commercialization team building and optimization.
"